Clinical Trial ProgressEncouraging preliminary data from COVALENT-101 and COVALENT-112 trials show potential efficacy of BMF-219 in blood cancers and T1D, with a well-tolerated safety profile.
Drug DevelopmentBMF-219 demonstrates promising clinical activity in T1D patients, with signs of improved β-cell function and potential long-term benefits.
Financial StabilityBiomea maintains a strong liquidity position with a significant cash reserve to support ongoing clinical trials.